Inflammatory Burden Index Associated with Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation.

IF 2.8 3区医学 Q1 Pharmacology, Toxicology and Pharmaceutics

Therapeutics and Clinical Risk Management Pub Date : 2025-05-15 eCollection Date: 2025-01-01 DOI:10.2147/TCRM.S518620

Siliang Peng, Feng Li, Mengchao Jin, You Zhang, Hui Li, Jiayu Yin

{"title":"Inflammatory Burden Index Associated with Recurrence of Atrial Fibrillation After Radiofrequency Catheter Ablation.","authors":"Siliang Peng, Feng Li, Mengchao Jin, You Zhang, Hui Li, Jiayu Yin","doi":"10.2147/TCRM.S518620","DOIUrl":null,"url":null,"abstract":"Background: Recurrence rates of atrial fibrillation (AF) remain high after radiofrequency catheter ablation (RFCA), and inflammation plays an important role in the process. Inflammatory burden index (IBI) as a new inflammatory marker has been found to be associated with worse prognosis in cardiovascular disease. But there are no studies on its role in predicting AF recurrence. The aim of this study was to assess the value of IBI in predicting recurrence of AF after RFCA.Methods: This was a single-center retrospective observational study. Consecutive enrolment of PersAF who underwent first-time radiofrequency ablation between January 2021 and June 2024. Inflammatory Burden Index (IBI) was calculated as C-reactive protein (CRP) × neutrophil/lymphocyte (NLR).Results: A total of 142 (27.2%) patients experienced recurrence after RFCA. Multivariate analysis showed that PersAF (OR = 1.599; 95% CI: 1.028 ~ 2.486, p = 0.018), CHA2DS2-VASc score≥2 (OR = 1.769; 95% CI: 1.142 ~ 2.741, p = 0.011), LAD (OR = 1.098; 95% CI: 1.054 ~ 1.145, p < 0.001) and IBI (OR = 1.028; 95% CI: 1.007 ~ 1.050, p = 0.009), were independent predictors of recurrence. ROC analysis shows superiority of IBI (AUC=0.695, 95% CI: 0.647 ~ 0.743, p < 0.001) over CRP and NLR in predicting AF recurrence. When IBI was integrated into the traditional model (including PersAF, LAD and CHA2DS2-VASc Score), the discrimination and reclassification accuracy for the recurrence were significantly improved.Conclusion: Inflammatory load index associated with the recurrence of AF after RFCA. Integration of IBI can improve the model about the recurrence of AF after RFCA.","PeriodicalId":22977,"journal":{"name":"Therapeutics and Clinical Risk Management","volume":"21 ","pages":"681-689"},"PeriodicalIF":2.8000,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12091244/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutics and Clinical Risk Management","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/TCRM.S518620","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Recurrence rates of atrial fibrillation (AF) remain high after radiofrequency catheter ablation (RFCA), and inflammation plays an important role in the process. Inflammatory burden index (IBI) as a new inflammatory marker has been found to be associated with worse prognosis in cardiovascular disease. But there are no studies on its role in predicting AF recurrence. The aim of this study was to assess the value of IBI in predicting recurrence of AF after RFCA.

Methods: This was a single-center retrospective observational study. Consecutive enrolment of PersAF who underwent first-time radiofrequency ablation between January 2021 and June 2024. Inflammatory Burden Index (IBI) was calculated as C-reactive protein (CRP) × neutrophil/lymphocyte (NLR).

Results: A total of 142 (27.2%) patients experienced recurrence after RFCA. Multivariate analysis showed that PersAF (OR = 1.599; 95% CI: 1.028 ~ 2.486, p = 0.018), CHA₂DS₂-VASc score≥2 (OR = 1.769; 95% CI: 1.142 ~ 2.741, p = 0.011), LAD (OR = 1.098; 95% CI: 1.054 ~ 1.145, p < 0.001) and IBI (OR = 1.028; 95% CI: 1.007 ~ 1.050, p = 0.009), were independent predictors of recurrence. ROC analysis shows superiority of IBI (AUC=0.695, 95% CI: 0.647 ~ 0.743, p < 0.001) over CRP and NLR in predicting AF recurrence. When IBI was integrated into the traditional model (including PersAF, LAD and CHA₂DS₂-VASc Score), the discrimination and reclassification accuracy for the recurrence were significantly improved.

Conclusion: Inflammatory load index associated with the recurrence of AF after RFCA. Integration of IBI can improve the model about the recurrence of AF after RFCA.

Abstract Image

查看原文本刊更多论文

射频导管消融后心房颤动复发与炎症负担指数相关。

背景：射频导管消融（RFCA）后心房颤动（AF）的复发率仍然很高，炎症在这一过程中起重要作用。炎症负担指数（Inflammatory burden index， IBI）作为一种新的炎症指标被发现与心血管疾病的预后不良有关。但其在预测房颤复发中的作用尚未见研究。本研究的目的是评估IBI在预测RFCA后房颤复发中的价值。方法：本研究为单中心回顾性观察性研究。在2021年1月至2024年6月期间连续入组首次接受射频消融的PersAF患者。炎症负担指数（IBI）计算为c反应蛋白（CRP） ×中性粒细胞/淋巴细胞（NLR）。结果：142例（27.2%）患者术后出现复发。多因素分析显示PersAF (OR = 1.599；95% CI: 1.028 ~ 2.486, p = 0.018)， CHA2DS2-VASc评分≥2 (OR = 1.769；95% CI: 1.142 ~ 2.741, p = 0.011), LAD (OR = 1.098；95% CI: 1.054 ~ 1.145, p < 0.001)和IBI (OR = 1.028；95% CI: 1.007 ~ 1.050, p = 0.009)是复发的独立预测因子。ROC分析显示IBI在预测AF复发方面优于CRP和NLR （AUC=0.695, 95% CI: 0.647 ~ 0.743, p < 0.001）。将IBI纳入传统模型（包括PersAF、LAD和CHA2DS2-VASc Score）后，对复发的判别和再分类准确率显著提高。结论：炎症负荷指数与RFCA术后房颤复发相关。综合IBI可改善RFCA术后AF复发模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutics and Clinical Risk Management HEALTH CARE SCIENCES & SERVICES-

CiteScore

5.30

自引率

3.60%

发文量

139

审稿时长

16 weeks

期刊介绍： Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines, therapeutic and surgical interventions in all clinical areas. The journal welcomes submissions covering original research, clinical and epidemiological studies, reviews, guidelines, expert opinion and commentary. The journal will consider case reports but only if they make a valuable and original contribution to the literature. As of 18th March 2019, Therapeutics and Clinical Risk Management will no longer consider meta-analyses for publication. The journal does not accept study protocols, animal-based or cell line-based studies.